Agios-JPM 2026_presentation_14 January 2026.pdf

《Agios-JPM 2026_presentation_14 January 2026.pdf》由会员分享，可在线阅读，更多相关《Agios-JPM 2026_presentation_14 January 2026.pdf（33页珍藏版）》请在三个皮匠报告上搜索。

1、J.P.Morgan Healthcare Conference 2026Agios Pharmaceuticals Brian Goff,Chief Executive Officer14 January 2026 Forward-Looking Statements2This presentation and various remarks we make during this presentation contain forward-looking statements within the meaning of The Private Securities Litigation Re

2、form Act of 1995.Such forward-looking statements include those regarding the potential benefits of AQVESMETM(mitapivat)and PYRUKYND(mitapivat);Agios plans for future meetings with,or submissions to,regulators,including the FDA;Agios plans for the development of mitapivat,tebapivat,AG-236 and AG-181;

3、Agios estimates regarding market sizes for various indications;and the potential benefits of Agios strategic plans and focus.The words“anticipate”,estimate,“expect”,“goal”,“hope”,“milestone”,“opportunity”,“plan”,“potential”,“possible”,“strategy”,“will”,“vision”,and similar expressions are intended t

4、o identify forward-looking statements,although not all forward-looking statements contain these identifying words.Such statements are subject to numerous important factors,risks and uncertainties that may cause actual events or results to differ materially from Agios current expectations and beliefs

5、.For example,there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases,or that development of any of Agios product candidates will successfully continue.There can be no guarantee that any posi

6、tive developments in Agios business will result in stock price appreciation.Managements expectations and,therefore,any forward-looking statements in this presentation and various remarks we make during this presentation could also be affected by risks and uncertainties relating to a number of other